India rifampicin market is expected to grow at a steady rate during the forecast period. Rifampicin is a semisynthetic antibiotic produced from Streptomyces, used to treat several types of bacterial infections. The India Rifampicin market is driven by increasing number of drug developments. Moreover, rifampicin is widely used to for the treatment of tuberculosis which is forecasted to positively influence the market growth. Ongoing research and developmental investments by key market players is further expected to boost the growth of India Rifampicin market through FY2026.

The India rifampicin market is segmented based on source, form, route of administration, distribution channel, application, end user, company, and region. Based on application, the market can be segmented into tuberculosis, leprosy, legionnaire's disease, others. Among these, tuberculosis segment is expected to dominate in the market over the coming years on account of high prevalence of tuberculosis in the country. Also, the efficient use of this drug for the treatment of tuberculosis and tuberculosis-related mycobacterial infections, is further bolstering the market growth.

The major players operating in the India rifampicin market are Indian Drugs and Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Lupin Laboratories Ltd., Concept Pharmaceuticals Ltd., Novartis India Ltd., Zydus Cadila Healthcare Ltd., Themis Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Taurus Laboratories Pvt. Ltd., and others. Major companies are developing advanced technologies and launching new products in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments to expand their geographic reach and to increase their customer basis.

Years considered for this report:

Historical Years: FY2016-FY2019

Base Year: FY2020

Estimated Year: FY2021

Forecast Period: FY2022–FY2026

Objective of the Study:

  • To analyze and estimate the market size of India rifampicin market from FY2016 to FY2019.
  • To estimate and forecast the market size of India rifampicin market from FY2020 to FY2026 and growth rate until FY2026.
  • To classify and forecast India rifampicin market based on source, form, route of administration, distribution channel, application, end user, company, and regional distribution.
  • To identify dominant region or segment in the India rifampicin market.
  • To identify drivers and challenges for India rifampicin market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in India rifampicin market.
  • To identify and analyze the profile of leading players operating in India rifampicin market.
  • To identify key sustainable strategies adopted by market players in India rifampicin market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of India rifampicin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.


Key Target Audience:

  • Rifampicin manufacturers/ suppliers/ distributors
  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to rifampicin

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, India rifampicin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • India Rifampicin Market, By Source:
    • In-house
    • Contract Manufacturing Organizations
  • India Rifampicin Market, By Form:
    • Tablet
    • Capsule
    • Injections
  • India Rifampicin Market, By Route of Administration:
    • Oral
    • Intravenous
  • India Rifampicin Market, By Distribution Channel:
    • Online
    • Offline
  • India Rifampicin Market, By Application:
    • Tuberculosis
    • Leprosy
    • Legionnaire's Disease
    • Others
  • India Rifampicin Market, By End User:
    • Adult
    • Paediatric
  • India Rifampicin Market, By Region:
    • North
    • South
    • East
    • West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in India rifampicin market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
India rifampicin market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]  

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Rifampicin Market

4.    Executive Summary

5.    Manufacturing Rifampicin

5.1.  Raw Material

5.2.  Machinery

5.3.  Manufacturing Methods

5.4.  Contact Details of Machinery & Raw Material Suppliers

6.    Pharmacodynamic Overview of Rifampicin

6.1.  Mechanism of Action

6.2.  Absorption

6.3.  Volume of Distribution

6.4.  Protein Binding

6.5.  Metabolism

6.6.  Route of Elimination

6.7.  Half-Life

6.8.  Clearance

6.9.  Toxicity

7.    India Rifampicin Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value & Volume

7.2.  Market Share & Forecast

7.2.1.     By Source (In-house v/s Contract Manufacturing Organizations)

7.2.2.     By Form (Tablet, Capsule and Injection)

7.2.3.     By Route of Administration (Oral v/s Intravenous)

7.2.4.     By Distribution Channel (Online v/s Offline)

7.2.5.     By Application (Tuberculosis, Leprosy, Legionnaire's Disease and Others)

7.2.6.     By End User (Adult v/s Paediatric)

7.2.7.     By Region (North, East, South, West)

7.2.8.     By Company

7.3.  Product Market Map

8.    Market Dynamics

8.1.  Drivers/Opportunities

8.2.  Challenges/Restraints

9.    Market Trends & Developments

10.  Policy & Regulatory Landscape

10.1.              Custom Duty & Taxes

10.2.              Government Subsidy & Benefits

10.3.              Relevant Policies & Regulations (GMP, USFDA, WHO Certifications)

11.  Import & Export Analysis

12.  Pricing Analysis

13.  India Economic Profile

14.  Competitive Landscape

14.1.              Company Profiles

14.1.1.  Indian Drugs and Pharmaceuticals Ltd.

14.1.1.1.      Company Brief

14.1.1.2.      Production Plants & Capacity (If Available)

14.1.1.3.      Financials (If Available)

14.1.1.4.      Captive Consumption Vs Merchant Sale

14.1.1.5.      Current & Future Plans

14.1.2.  Cadila Pharmaceuticals Ltd.

14.1.3.  Macleods Pharmaceuticals Ltd.

14.1.4.  Lupin Laboratories Ltd.

14.1.5.  Concept Pharmaceuticals Ltd.

14.1.6.  Novartis India Ltd.

14.1.7.  Zydus Cadila Healthcare Ltd.

14.1.8.  Themis Pharmaceuticals Ltd.

14.1.9.  GlaxoSmithKline Pharmaceuticals Ltd.

14.1.10.                Taurus Laboratories Pvt. Ltd.

15.  Strategic Recommendations

16.  About Us & Disclaimer